Teva Pharmaceutical Industries Ltd., which makes generic drugs, said it received a subpoena from U.S. regulators in connection with a bribery investigation in Latin America.
Teva is cooperating with the Securities and Exchange Commission's July 9 request to provide documents on compliance with the Foreign Corrupt Practices Act, the Israeli-based company said Thursday in a regulatory filing. The company has its headquarters for the Americas in North Wales, Pa.
Drugmakers and makers of medical devices have reported getting requests in the last year for information from U.S. prosecutors and regulators on compliance with the act in Europe and South America. The law bars corporate employees or their agents from paying bribes to government officials to obtain or retain business. Olympus Corp. said Aug. 1 it had uncovered "irregularities" at a doctor-training program in Brazil that may have violated the U.S. law. Wal-Mart Stores Inc. also was snared in a corrupt practices probe in Mexico this year.
